Theseus Pharmaceuticals, Inc.
(NASDAQ : THRX)

( )
THRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.72%174.070.0%$1639.17m
NVAXNovavax, Inc. -6.21%92.3378.2%$633.32m
AMGNAmgen, Inc. -1.08%231.301.4%$520.34m
BIIBBiogen, Inc. -1.28%230.811.8%$499.50m
GILDGilead Sciences, Inc. -1.93%69.071.0%$465.79m
BNTXBioNTech SE -4.47%161.660.0%$438.57m
REGNRegeneron Pharmaceuticals, Inc. 1.13%618.112.7%$392.67m
ILMNIllumina, Inc. 0.32%384.363.3%$386.08m
VRTXVertex Pharmaceuticals, Inc. -0.10%230.841.9%$334.35m
SNSSSunesis Pharmaceuticals, Inc. -4.00%2.880.7%$201.32m
EXASEXACT Sciences Corp. -1.67%76.1317.9%$160.64m
ARNAArena Pharmaceuticals, Inc. -0.51%91.5113.7%$138.71m
ALNYAlnylam Pharmaceuticals, Inc. -0.41%138.628.2%$131.51m
INCYIncyte Corp. -0.31%74.782.4%$129.60m
BBIOBridgeBio Pharma, Inc. -0.51%11.700.0%$104.26m

Company Profile

Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA.